Juan Zhao, Jia Li, Ling-Ling Qian, Zuo-Feng Ding, Li Zhang
{"title":"[肌少症对急性髓系白血病患者治疗反应及预后的预测价值]。","authors":"Juan Zhao, Jia Li, Ling-Ling Qian, Zuo-Feng Ding, Li Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of sarcopenia on therapeutic response and prognosis of newly diagnosed acute myeloid leukemia (AML) patients, and reveal its predictive value for the clinical outcomes of AML patients.</p><p><strong>Methods: </strong>A total of 122 AML patients who were initially diagnosed and treated with induction chemotherapy at the Department of Hematology in the Affiliated Hospital of Nantong University from January 2017 to December 2020 were included in this study. The sarcopenia was diagnosed by measuring body composition parameters with multifrequency bioelectrical impedance analyzer, and all AML patients were divided into sarcopenia and non-sarcopenia groups. Kaplan-Meier curves and log-rank test were used to compare the survival difference between the two groups. The relationship between sarcopenia and overall survival (OS) of AML patients was further determined by the univariate and multivariate Cox regression analysis.</p><p><strong>Results: </strong>Among 122 AML patients, 46 (37.7%) were diagnosed with sarcopenia before induction chemotherapy. The body mass index (BMI) of patients with sarcopenia was significantly lower than that of non-sarcopenia patients ( <i>t</i> =4.258, <i>P</i> <0.001), and the complete response (CR) and partial response (PR) rates of sarcopenia patients after induction chemotherapy were significantly lower than those of nonsarcopenia patients (χ<sup>2</sup>=6.348, <i>P</i> =0.042). Kaplan-Meier curves showed that sarcopenic patients had a shorter OS than non-sarcopenic patients, and the median OS of the two groups were 20.7 (95%<i>CI</i> : 12.6-27.8) months and 27.8 (95%<i>CI</i> : 22.3-31.9) months, respectively (χ<sup>2</sup>= 5.659, <i>P</i> =0.017). Subgroup analysis indicated that the median OS of sarcopenic and non-sarcopenic AML patients who received standard induction chemotherapy were 12.2 (95%<i>CI</i> : 5.4-24.7) months and 26.1 (95%<i>CI</i> : 16.7-35.4) months, respectively (χ<sup>2</sup>=3.949, <i>P</i> =0.047). The multivariate Cox regression analysis revealed that sarcopenia (<i>HR</i>=1.671, 95%<i>CI</i> : 1.034-2.701, <i>P</i> =0.036) was an independent predictor for poor prognosis in AML patients.</p><p><strong>Conclusion: </strong>Sarcopenia is significantly associated with low response rate of induction chemotherapy and poor prognosis in AML patients, and it might be an useful tool for predicting the clinical outcome of AML patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1016-1022"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Predictive Value of Sarcopenia for Therapeutic Response and Prognosis in Patients with Acute Myeloid Leukemia].\",\"authors\":\"Juan Zhao, Jia Li, Ling-Ling Qian, Zuo-Feng Ding, Li Zhang\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2025.04.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To investigate the effects of sarcopenia on therapeutic response and prognosis of newly diagnosed acute myeloid leukemia (AML) patients, and reveal its predictive value for the clinical outcomes of AML patients.</p><p><strong>Methods: </strong>A total of 122 AML patients who were initially diagnosed and treated with induction chemotherapy at the Department of Hematology in the Affiliated Hospital of Nantong University from January 2017 to December 2020 were included in this study. The sarcopenia was diagnosed by measuring body composition parameters with multifrequency bioelectrical impedance analyzer, and all AML patients were divided into sarcopenia and non-sarcopenia groups. Kaplan-Meier curves and log-rank test were used to compare the survival difference between the two groups. The relationship between sarcopenia and overall survival (OS) of AML patients was further determined by the univariate and multivariate Cox regression analysis.</p><p><strong>Results: </strong>Among 122 AML patients, 46 (37.7%) were diagnosed with sarcopenia before induction chemotherapy. The body mass index (BMI) of patients with sarcopenia was significantly lower than that of non-sarcopenia patients ( <i>t</i> =4.258, <i>P</i> <0.001), and the complete response (CR) and partial response (PR) rates of sarcopenia patients after induction chemotherapy were significantly lower than those of nonsarcopenia patients (χ<sup>2</sup>=6.348, <i>P</i> =0.042). Kaplan-Meier curves showed that sarcopenic patients had a shorter OS than non-sarcopenic patients, and the median OS of the two groups were 20.7 (95%<i>CI</i> : 12.6-27.8) months and 27.8 (95%<i>CI</i> : 22.3-31.9) months, respectively (χ<sup>2</sup>= 5.659, <i>P</i> =0.017). Subgroup analysis indicated that the median OS of sarcopenic and non-sarcopenic AML patients who received standard induction chemotherapy were 12.2 (95%<i>CI</i> : 5.4-24.7) months and 26.1 (95%<i>CI</i> : 16.7-35.4) months, respectively (χ<sup>2</sup>=3.949, <i>P</i> =0.047). The multivariate Cox regression analysis revealed that sarcopenia (<i>HR</i>=1.671, 95%<i>CI</i> : 1.034-2.701, <i>P</i> =0.036) was an independent predictor for poor prognosis in AML patients.</p><p><strong>Conclusion: </strong>Sarcopenia is significantly associated with low response rate of induction chemotherapy and poor prognosis in AML patients, and it might be an useful tool for predicting the clinical outcome of AML patients.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":\"33 4\",\"pages\":\"1016-1022\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.04.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.04.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨肌肉减少症对新诊断急性髓性白血病（AML）患者治疗反应及预后的影响，揭示其对AML患者临床预后的预测价值。方法：选取2017年1月至2020年12月在南通大学附属医院血液科首次诊断并接受诱导化疗的AML患者122例。采用多频生物电阻抗分析仪测定机体组成参数诊断肌少症，将所有AML患者分为肌少症组和非肌少症组。采用Kaplan-Meier曲线和log-rank检验比较两组患者的生存差异。通过单因素和多因素Cox回归分析进一步确定骨骼肌减少症与AML患者总生存期（OS）的关系。结果：122例AML患者中，46例（37.7%）在诱导化疗前确诊为肌肉减少症。肌少症患者的体重指数（BMI）显著低于非肌少症患者（t =4.258, P 2=6.348, P =0.042）。Kaplan-Meier曲线显示，肌减少症患者的生存期短于非肌减少症患者，两组的中位生存期分别为20.7 （95%CI: 12.6 ~ 27.8）个月和27.8 （95%CI: 22.3 ~ 31.9）个月，差异有统计学意义（χ2= 5.659, P =0.017）。亚组分析显示，接受标准诱导化疗的骨骼肌减少和非骨骼肌减少AML患者的中位OS分别为12.2 （95%CI: 5.4 ~ 24.7）个月和26.1 （95%CI: 16.7 ~ 35.4）个月（χ2=3.949, P =0.047）。多因素Cox回归分析显示，肌少症（HR=1.671, 95%CI: 1.034-2.701, P =0.036）是AML患者预后不良的独立预测因子。结论：骨骼肌减少症与AML患者诱导化疗反应率低、预后差有显著相关性，可作为预测AML患者临床预后的有用工具。
[Predictive Value of Sarcopenia for Therapeutic Response and Prognosis in Patients with Acute Myeloid Leukemia].
Objective: To investigate the effects of sarcopenia on therapeutic response and prognosis of newly diagnosed acute myeloid leukemia (AML) patients, and reveal its predictive value for the clinical outcomes of AML patients.
Methods: A total of 122 AML patients who were initially diagnosed and treated with induction chemotherapy at the Department of Hematology in the Affiliated Hospital of Nantong University from January 2017 to December 2020 were included in this study. The sarcopenia was diagnosed by measuring body composition parameters with multifrequency bioelectrical impedance analyzer, and all AML patients were divided into sarcopenia and non-sarcopenia groups. Kaplan-Meier curves and log-rank test were used to compare the survival difference between the two groups. The relationship between sarcopenia and overall survival (OS) of AML patients was further determined by the univariate and multivariate Cox regression analysis.
Results: Among 122 AML patients, 46 (37.7%) were diagnosed with sarcopenia before induction chemotherapy. The body mass index (BMI) of patients with sarcopenia was significantly lower than that of non-sarcopenia patients ( t =4.258, P <0.001), and the complete response (CR) and partial response (PR) rates of sarcopenia patients after induction chemotherapy were significantly lower than those of nonsarcopenia patients (χ2=6.348, P =0.042). Kaplan-Meier curves showed that sarcopenic patients had a shorter OS than non-sarcopenic patients, and the median OS of the two groups were 20.7 (95%CI : 12.6-27.8) months and 27.8 (95%CI : 22.3-31.9) months, respectively (χ2= 5.659, P =0.017). Subgroup analysis indicated that the median OS of sarcopenic and non-sarcopenic AML patients who received standard induction chemotherapy were 12.2 (95%CI : 5.4-24.7) months and 26.1 (95%CI : 16.7-35.4) months, respectively (χ2=3.949, P =0.047). The multivariate Cox regression analysis revealed that sarcopenia (HR=1.671, 95%CI : 1.034-2.701, P =0.036) was an independent predictor for poor prognosis in AML patients.
Conclusion: Sarcopenia is significantly associated with low response rate of induction chemotherapy and poor prognosis in AML patients, and it might be an useful tool for predicting the clinical outcome of AML patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
